StandoutStocks.com: StandoutStocks.com "Stocks that Standout" today are: EREI, FORC, GOVX, HYII, IVIT, RSMI

Jul 22, 2008 (M2 PRESSWIRE via COMTEX) -- RSMIE | Quote | Chart | News | PowerRating -- July 22, 2008 StandoutStocks.com "Stocks that Standout" today are: EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI), Force Energy Corp. (OTCBB: FORC), GeoVax Labs, Inc. (OTCBB: GOVX), Hybred International, Inc.(OTCBB: HYII), Invicta Group Inc. (OTCBB: IVIT), Rim Semiconductor Company (OTCBB: RSMI),

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Jul 22, 2008 -- EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI), (EAGLE ROCK), announced today that the Company has signed a letter of intent to acquire MPD, a distributing and warehousing company. MPD maintains a national logistics base. Their experience in international shipping will provide EAGLE ROCK with the necessary support systems for current and future business development.

MPD will provide a strategic plan to implement EAGLE ROCK'S domestic and international marketing programs. MPD is the key link in the vertical integration process that allows EAGLE ROCK to produce and sell products worldwide, and in return, purchase from foreign markets to distribute in the United States.

Jul 22, 2008 -- Force Energy Corp. (OTCBB: FORC | Quote | Chart | News | PowerRating) (hereafter "Force", "the Company") announces a 20% working interest in the Hayter Well (10D Hayter 10-8-40-1 W4M) located in Alberta, Canada. The well was spudded in January 2007 and drilled to a total depth. The well logs revealed a gas zone of 4 to 5 meters of thickness in a shallow zone and a heavy oil pay zone of 2 meters of thickness in the target Dina Sand zone. Although the results in the Dina sand were lower than expected and a decision was made to case the well in 2007, at today's prices, the Hayter could produce an economic well.

County Line Energy completed a $650,000 3D seismic program covering nine sections of land in pursuit of a potential multi well heavy oil drilling opportunity. The geological model was based on interpretation from a previous well, which produced 16,000 barrels of heavy oil. The seismic program was designed to determine whether the structure found in this well existed to a larger extent on the subject property. The 3D seismic revealed an extremely large anomaly with similar characteristics. The nature of this large anomaly suggested that a multi well drilling opportunity might exist. Although this well will likely be completed as a producing well the results of the drilling have negated the ultimate potential of the Hayter property.

About the Purchase of Interest in the Hayter Well

On August 1, 2006, County Line Energy Corp. ("County Line") signed a participation agreement with Black Creek Resources Ltd. ("BCR") in which County Line acquired the right to become the operator and drill the Hayter well (10D Hayter 10-8-40-1 W4M) located in Alberta, Canada. In order to exercise that interest and acquire the rights to drill the Hayter well, County Line agreed to pay 100% of all costs associated with the seismic option agreement and pay 100% of the funds required to purchase rights to any existing seismic on the property which may be for sale and or shoot additional 2D and 3D on the property as required, pursuant to standard industry costs and practices.

Pursuant to a Participation Agreement dated December 21, 2006 between Black Creek Resources Ltd ("BCR") and Nuance Exploration Ltd. ("NEL"), a wholly owned subsidiary of the Company, we acquired a 100% ownership in the interpretation of 3D seismic data covering four sections of certain land located in the province of Alberta, Canada by paying $82,650 for the purpose of acquiring and interpreting the seismic data. On October 15, 2007, prior to the evaluation of the 3D seismic data, County Line sold to BCR its 100% interest in the subject property and received as consideration a non-interest bearing promissory note for $111,144 (CDN$110,000) to be repaid by November 30, 2007.

On November 30, 2007, County Line did not repay the amounts owing pursuant to the promissory note and NEL and County Line entered into a Participation Agreement whereby NEL accepted a 20% interest of the Grantor's working interest in the County Line 10D Hayter 10-8-40-1 W4M well as full and final settlement of the promissory note. Pursuant to the terms of the Participation agreement NEL will assume 20% of all revenues, costs and expenses associated with the project.

About Force Energy Corp.

Force Energy Corp. is an Oil & Gas Exploration and Development Company based in Denver, CO with a focus on Wyoming. Using a geology-based methodology, the US Geological Survey estimate a mean of 2.4 trillion cubic feet of undiscovered natural gas, a mean of 41 million barrels of undiscovered oil, and a mean of 20.5 million barrels of undiscovered natural gas liquids in the Wind River Basin Province of Wyoming. They further estimate a mean of 84.6 trillion cubic feet of undiscovered natural gas, a mean of 131 million barrels of undiscovered oil, and a mean of 2.6 billion barrels of undiscovered natural gas liquids in the Southwestern Wyoming Province. Force Energy Corp. has entered into LOI's to drill and develop two prospects located within each of these prolific areas. The Company's shares are publicly traded on the OTCBB under the ticker symbol FORC.

July 22, 2008 -- GeoVax Labs, Inc. (OTCBB: GOVX), an Atlanta based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, together with Vivalis (NYSE Euronext: VLS), a French biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, announced today the signing of a letter of intent (LOI) for joint collaboration and commercial license on the use of Vivalis' EBx(R) technology, to manufacture the MVA component of the GeoVax HIV-1 vaccine.

This agreement between GeoVax and Vivalis creates a worldwide strategic partnership between Vivalis and GeoVax, designed to combine Vivalis' cutting-edge vaccine manufacturing technology with GeoVax's promising HIV vaccine.

The breakthrough manufacturing technology developed by Vivalis, and now to be further developed through collaboration with GeoVax, will create a new standard for manufacture of the MVA component of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited production capabilities, less competitive. Vivalis' EBx(R) manufacturing platform, with its increased effectiveness, superior quality and reliability, will speed time to market MVA vaccine product availability in ample quantities to meet sizeable demand and expectedly at a lesser cost.

"Partnering with Vivalis and its cutting-edge technology is extremely significant, and a giant step forward for efficient manufacturing of our 'MVA' HIV/AIDS vaccine component," stated Robert McNally, President and CEO, GeoVax.

"Vivalis is pleased to enter in this collaboration with GeoVax, one of the most advanced companies worldwide in the field of HIV vaccine development. This agreement aims at developing a Vivalis proprietary upstream-downstream process for the production of MVA vaccines and EBx(R) technology licensing. GeoVax becomes a strategic partner and joins an elite worldwide consortium in the field of development, purification and production of MVA based vaccines," said Franck Grimaud, Vivalis CEO.

The EB66(R) cell line is becoming a new standard for the production of vaccines, leading to Vivalis having signed more than 20 licenses prior to December 2007 and four licenses in 2008: two research and two commercial.

Vivalis' vaccine manufacturing technology is based on a duck embryonic stem cell substrate platform. The EB66(R) cell line provides continuous growth from a fully characterized frozen cell bank, without necessitating fertilized embryo extraction and processing, as with present chicken cell based technologies. Furthermore, the EB66(R) cell line can be grown in suspension (without the cells attached to the surface of the growth vessel) and can be scaled up for growth in giant bioreactors (a cutting edge industrial method) for large scale production of the MVA viral vaccine.

Last month, Vivalis announced the filing of the BMF (Biologics Master File) for the EB66(R) cell line with the US FDA (Food and Drug Administration). Extensive testing reveals the unique and innovative nature of Vivalis EBx(R) technology for the production of vaccines and proteins. Today, the EB66(R) cell line is the only available cell line in the market to be immortal and diploid.

"When we learned about the work of Vivalis with EBx(R) cell lines that might be able to be used to grow MVA, we contacted Vivalis and arranged with them to jointly conduct pilot studies on the growth of our MVA vaccine," said Harriet Robinson, Senior Vice President of Research and Development, GeoVax. "Our early production results have been very promising and have led to this LOI for more formal development of the Vivalis EB66(R) cell line for the production of our MVA vaccine."

The GeoVax vaccine is a DNA/MVA vaccine that uses recombinant DNA to prime the immune response and then a recombinant MVA virus to boost the immune response. MVA stands for Modified Vaccinia Ankara, a smallpox viral vaccine that was attenuated (made more safe) by replicating the vaccine virus over 500 times in chicken cells. This long series of replications resulted in a derivative of the smallpox vaccine virus which could grow in chicken cells but that had limited ability to grow in human cells. The poor ability to grow on human cells has made MVA a very safe vaccine vector for humans. However, it also limited the ability to manufacture MVA in the industrial cell lines that have been approved for vaccine production. Rather, MVA had to be grown in chicken cells which rely on harvesting cells from thousands of chicken embryos and using these cells which are grown in multiple small vessels for vaccine manufacture. This process can be done for clinical and commercial production, but is cumbersome, fraught by the introduction of contaminants and expensive. The Vivalis EBx(R) manufacturing technology eliminates such difficulties and enables rapid large scale production in bioreactors for GeoVax's future commercial needs.

Financial terms of the agreement have not been disclosed. However, each side shall fund its roles respectively, depending on developmental or process responsibilities assumed by each party. An upfront amount payable to Vivalis will be provided as consideration for the signing of the LOI. GeoVax's development and license payments shall be made based on milestone achievements. Royalties on GeoVax net sales are also included. In addition, applications have been filed for EU and local government financial participation. GeoVax is also seeking FDA guidance on the Vivalis EBx(R) manufacturing program recently submitted to the USA FDA allowing usage of EB66(R) produced MVA vaccine for GeoVax's ongoing human trials.

Earlier this month, GeoVax also announced an operational update on the company's progress towards entering Phase 2 preventative human clinical trial testing and plans to proceed into therapeutic human trials with its AIDS vaccine. The Company's Phase 2 trial, to be conducted by the U.S. National Institutes of Health (NIH) and supported HIV Vaccine Trials Network (HVTN), will involve 225 healthy volunteers from the United States and South America, and will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the AIDS virus). The GeoVax DNA/MVA vaccine uses a different viral vector (MVA) than the Merck vaccine and the NIH Vaccine Research Center vaccines, which use adenovirus5 (Ad5) vectors. The Merck vaccine was withdrawn from trials in September 2007 because of failure to protect. The NIH has just announced that their vaccine will not be progressing in large scale trials because of the Merck results. Thus two major competitors for GeoVax are no longer progressing in trials.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax HIV/AIDS vaccines also may be effective as therapeutics (treatment of people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007.

About Vivalis

Vivalis (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. Vivalis's expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. Vivalis offers research and commercial licenses for its EB66(R) cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. Vivalis receives up front, milestones, and royalties on its licensees net sales.

2. The development of production systems for recombinant proteins and monoclonal antibodies. Vivalis licenses its EB66(R) cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties on its licensees net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Jul 21, 2008 -- Hybred International, Inc.(OTC: HYII | Quote | Chart | News | PowerRating) was established in 2005 and became a publicly traded company earlier in Q1 2008.

The Company believes it successfully created the next-generation therapeutic horseshoe and is pleased to share the following information.

Corporate Web Site:

www.hybredhorseshoe.com.

About the Hybred Horseshoe:

The Hybred Horseshoe was created to address the number one problem in the equine industry - hoof injuries which account for nearly 90% of all potentially serious and often detrimental injuries to horses employed in all sectors of the equestrian market.

The Hybred Horseshoe is comprised of a polyurethane molding which once attached to an aluminum horse shoe thus becomes a shock absorber and protects the horse's hooves and joints from deterioration caused by running on hard surfaces such as concrete, asphalt and race tracks. In addition, its design features enable the farrier the use traditional shoeing methods.

Primary Marketing Partner:

The Company has signed an agreement with Thoro'bred, the world's largest manufacturer of horseshoes. Under the terms of the agreement, Thoro'bred will manufacture, market and distribute the Hybred Horseshoe and market the product through its well-established world-wide distribution network.

About the Equine Industry:

The equine industry is approximately a $39 Billion industry according to a study published in 2005 by Deloitte Consulting LLP for the American Horse Council Foundation. Over 4.6 million people are engaged in the industry as horse owners, service providers, employees and volunteers; Tens of millions of other are spectators in equestrian events in one form or another.

The study also showed that the industry directly produces goods and services of $38.8 Billion, with a total impact of $101.5 Billion on the U.S. Gross Domestic Product.

About the Horse Shoe Market:

In the US alone, there are approximately 9 million horses that requiring shoeing each month. Considering that a shoeing is four horseshoes per horse each month for 9 million horses, the total horseshoe market in the United States is estimated at $432 million per annum.

Based on the foregoing, the horse shoe industry, exclusive of any labor and tooling, is approximately $3.2 Billion a year.

There are more than 52 million horses outside the United States, thus representing a potential market opportunity of an additional $18.7 Billion.

Jul 22, 2008 -- Invicta Group Inc. (OTCBB: IVIT | Quote | Chart | News | PowerRating) announces the launch of www.TicketHotLink.com, a new division to offer and process online ticket sales. Invicta group Inc. is blending its online traffic from over 50 websites, with its 25,000,000-email database, and the marketing power of its new marketing firm IMAGE Worldwide, Inc. (PINKSHEETS: IMGW) to offer a new online service. This year the Company expects revenues of around $25,000; $100,000 in 2009 and $250,000 in 2010.

www.TicketHotLink.com allows online users to search 1000s of venues for 100,000s of tickets for sporting events, concerts, and other special events.

Invicta's CEO Paul Sorkin said, "Ticket sales offer a perfect tie-in for our online users looking for travel packages that may include airline tickets, hotel reservations, car rentals, and now tickets to that special event. We are going to continue to launch new divisions that will add to our bottom line over the coming months; with all of our divisions, we expect to see healthy growth over the coming months and years."

About IMAGE Worldwide, Inc.

IMAGE Worldwide, Inc. (PINKSHEETS: IMGW) is a full service interactive multimedia marketing and advertising agency. IMAGE is vertically integrated with properties including a concert/nightclub venue, fashion/entertainment magazine, high-end direct mailing book, IT solutions company, along with other promotional and marketing companies. IMAGE utilizes a combination of different forms of media and promotions to help clients showcase and market their IMAGE in print, Internet, event planning, radio, and TV.

About Invicta Group Inc.

INVICTA GROUP INC. (OTCBB: IVIT | Quote | Chart | News | PowerRating) is an Internet Media Company that specializes in the Travel and Entertainment Industry. The company has a subsidiary that uses the Internet as their media to generate revenues: Travel Hot Link links travel enthusiasts with products to fulfill their travel and entertainment needs. Travel Hot Link sells its Internet database of 25 million travel enthusiasts to Travel Suppliers that want to promote their discounted travel products: airline tickets, hotel rooms, tour packages, rental cars, cruise cabins, and more on the Internet 24/7.

Jul 22, 2008 -- Rim Semiconductor Company (OTCBB: RSMI), a company that develops technology for telecommunications service providers, announced today that it has reduced its indebtedness to its convertible note holders by 34% to $2,759,000, versus $4,182,000, as reported in its most recent 10QSB.

The reduction was effected when holders of its two-year 7% Senior Secured Convertible Debentures and its two-year 10% Secured Convertible Notes converted some of their principal and interest into shares of Rim Semi's Common Stock. The company has 4 billion shares of common stock authorized for issuance. As of July 11, 2008, following the issuance of the shares, the Company has issued all of its authorized common stock. Since July 11th, the closing price of RSMI has risen 100% from $0.0005 to $0.001 per share.

"I am very pleased that our convertible debt has reduced by 34%," stated Brad Ketch, the company's president and chief executive officer. "We issued these shares to investors who have invested in us before, and who continue to show support for our long-term growth."

In addition to the debt reduction, the company projects that the value of the derivative liability on its balance sheet will also proportionately decline when the derivative liability calculations are made at the end of the quarter, and based upon the closing price of RSMI on July 31, 2008.

About Rim Semiconductor Company

Rim Semiconductor Company (OTCBB: RSMI | Quote | Chart | News | PowerRating) develops technology for telecommunications companies to deliver demanding new video and data services with lower network costs. The company's products allow data to be transmitted at greater speed and across extended distances over existing copper wire--all with the highest quality of service--for a better end-user experience.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: StandoutStocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index